Biofrontera Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Biofrontera Inc. is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, with a primary focus on photodynamic therapy (PDT) and topical antibiotics. Its core products include Ameluz, a prescription topical drug used in combination with the proprietary BF-RhodoLED lamp series for PDT to treat actinic keratosis (AK), a precancerous skin lesion, and Xepi, a topical non-fluorinated quinolone antibiotic cream used to treat impetigo, a bacterial skin infection. The company’s product portfolio addresses skin conditions caused primarily by sun exposure and bacterial infections. Biofrontera operates primarily in the United States and conducts commercial activities including manufacturing, regulatory, quality management, pharmacovigilance, and sales through its headquarters in Woburn, Massachusetts. The company was founded in 2015 and is part of the broader Biofrontera Group, headquartered in Germany. Recent major changes at Biofrontera Inc. include the acquisition of all U.S. assets related to Ameluz and the BF-RhodoLED lamps from its parent company Biofrontera AG, which streamlined its operations by enabling full control over regulatory, commercial, and manufacturing responsibilities within the U.S. market. This acquisition was supported by an $11 million financing round aimed at propelling the company toward profitability while reducing royalty rates for U.S. sales. Additionally, in late 2025, Biofrontera sold the license for its antibiotic product Xepi to Pelthos Therapeutics Inc. for up to $10 million, focusing its resources on the PDT franchise. The company has also filed a supplemental new drug application (sNDA) for expanding the indication of Ameluz in treating superficial basal cell carcinoma (sBCC), highlighting ongoing development and regulatory efforts. In terms of strategic alliances, Biofrontera entered a distribution agreement for Ameluz in Croatia, expanding its geographic reach. Biofrontera targets dermatology healthcare providers and patients requiring treatment for pre-cancerous and bacterial skin conditions, with its products used in both lesion-directed and field-directed therapies. The company's business segments focus on specialty pharmaceuticals in dermatology, emphasizing innovative treatment modalities such as photodynamic therapy. Biofrontera Inc. went public in October 2021 and continues to leverage its proprietary nanotechnology formulations in topical drugs to enhance clinical efficacy and skin penetration. In summary, Biofrontera Inc. is a U.S.-based biopharmaceutical company engaged in the development, manufacturing, and commercialization of dermatology-focused pharmaceutical products centered on photodynamic therapy and topical antibiotics. It has recently restructured ownership and operational control of its key products in the U.S., launched new regulatory filings to broaden treatment indications, and realigned its portfolio by divesting non-core assets to enhance focus and profitability in the dermatology sector. The company’s headquarters is in Woburn, Massachusetts, and it operates within the competitive specialty pharmaceutical industry.
Company News
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
Biofrontera Q4 Earnings Call Highlights
Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable
Contrasting Biofrontera (NASDAQ:BFRI) & RenovaCare (OTCMKTS:RCAR)